Reata Pharmaceuticals, Inc. (NASDAQ:RETA) was the recipient of some unusual options trading activity on Tuesday. Stock investors purchased 1,682 put options on the stock. This represents an increase of 1,068% compared to the typical daily volume of 144 put options.
Shares of RETA opened at $97.18 on Thursday. The firm has a market cap of $3.52 billion, a P/E ratio of -8.56 and a beta of 1.57. Reata Pharmaceuticals has a 12-month low of $88.17 and a 12-month high of $186.82. The company’s 50-day moving average price is $115.94 and its 200 day moving average price is $122.29.
Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings data on Monday, March 1st. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.14) by $0.24. The firm had revenue of $3.19 million for the quarter, compared to analyst estimates of $1.20 million. Reata Pharmaceuticals had a negative net margin of 4,340.72% and a negative return on equity of 163.42%. Reata Pharmaceuticals’s revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($5.91) EPS. As a group, research analysts anticipate that Reata Pharmaceuticals will post -7.87 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the stock. Woodstock Corp increased its stake in shares of Reata Pharmaceuticals by 0.7% during the first quarter. Woodstock Corp now owns 21,217 shares of the company’s stock worth $2,115,000 after buying an additional 150 shares during the period. Dumac Inc. purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $9,401,000. Teachers Retirement System of The State of Kentucky increased its stake in shares of Reata Pharmaceuticals by 7.0% during the fourth quarter. Teachers Retirement System of The State of Kentucky now owns 41,056 shares of the company’s stock worth $5,075,000 after buying an additional 2,686 shares during the period. Laurel Wealth Advisors Inc. purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $302,000. Finally, Norges Bank purchased a new stake in shares of Reata Pharmaceuticals during the fourth quarter worth approximately $24,820,000. Hedge funds and other institutional investors own 64.30% of the company’s stock.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others.
Featured Story: Environmental, Social, and Governance (ESG) Investing
Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.